Control and Prevention (CDC) announces the following committee meetings.

Name: Advisory Committee for Energy-Related Epidemiologic Research (ACERER).

Times and Dates: 8:30 a.m.–5 p.m., April 20, 1999; 8:30 a.m.–5 p.m., April 21, 1999.

Place: Hyatt Regency Knoxville, 500 Hill Avenue SE, Knoxville, Tennessee 37915, telephone 423/637–1234, fax 423/522–5911.

Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 100 people.

Purpose: This committee is charged with providing advice and recommendations to the Secretary, HHS; the Assistant Secretary for Health; the Director, CDC; and the Administrator, Agency for Toxic Substances and Disease Registry (ATSDR), on establishment of a research agenda and the conduct of a research program pertaining to energy-related analytic epidemiologic studies.

Matters to be Discussed: Agenda items will include update presentations from the National Center for Environmental Health (NCEH), the National Institute for Occupational Safety and Health (NIOSH), and ATSDR on the progress of current studies and proposed research agendas; a presentation of the historical overview of ACERER; a review of current NCEH and NIOSH research agendas; a discussion of prospective studies of clean-up workers—Government and community; an explanation of how the Subcommittee for Community Affairs (SCA) relates to the full ACERER; a discussion of the continuing issues related to the National Cancer Institute (NCI) report; a discussion of research agenda formulation; and a report on community health centers.

Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Michael J. Sage, Executive Secretary, ACERER, and Acting Deputy Director, Division of Environmental Hazards and Health Effects (DEHHE), NCEH, CDC 4770 Buford Highway, NE, (F28), Atlanta, Georgia 30341–3724, telephone 770/488–7044.

Name: Subcommittee for Community Affairs (SCA), ACERER

Time and Date: 8:30 p.m.–5 p.m., April 22, 1999.

Place: Oak Ridge Mall, 333 Main Street, Oak Ridge, Tennessee 37830, telephone 423/482–2008, fax 423/481–3429.

Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 100 people.

Purpose: This subcommittee advises ACERER on matters related to community needs.

Matters to be Discussed: Agenda items will include update presentations from NCEH, NIOSH, and ATSDR on the progress of current studies; a discussion of subcommittee recommendations and public involvement activities. There will also be an update on the SCA work group progress.

Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Steven A. Adams, Executive Secretary, SCA, ACERER, Radiation Studies Branch, DEHHE, NCEH, CDC, 4770 Buford Highway, NE, (F–28), Atlanta, Georgia 30341–3724, telephone 770/488–7040, fax 770/488–7044.

The Director, Management Analysis and Services Office has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities for both the CDC and ATSDR.

Dated: March 25, 1999.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 99–8411 Filed 4–5–99; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC) Announces the Following Meeting

Name: Study Protocol Peer Review Meeting: Lung Cancer Among Workers Exposed to External Ionizing Radiation.

Time and Date: 9 a.m.–3:30 p.m., May 24, 1999.

Place: NIOSH, Hamilton Laboratories, Hamilton Auditorium, 5555 Ridge Avenue, Cincinnati, Ohio 45213.

Status: Open to the public, limited by the space available. The meeting room accommodates approximately 50 people.

Purpose: The purpose of this meeting is to obtain expert advice regarding technical and scientific aspects of the study ''Multi-Site Case-Control Study of Lung Cancer and External Ionizing Radiation'' being conducted at NIOSH. Participants on the Peer Review Panel will review the study protocol and advise on the conduct of the study. Viewpoints and suggestions from industry, labor, academia, other government agencies and the public are invited.

Contact Person for More Information: Larry J. Elliott, MSPH, C.I.H., Health-Related Energy Research Branch, Division of Surveillance, Hazard Evaluations, and Field Studies, NIOSH, CDC, 4676 Columbia Parkway, M/S R–44, Cincinnati, Ohio 45226, telephone 513/841–4400.

The Director, Management Analysis and Services office has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: March 25, 1999.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 99–8404 Filed 4–5–99; 8:45 am]

BILLING CODE 4160–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Interim Polio Vaccine Information Materials; New Vaccine Information Materials for Hepatitis B, Haemophilus Influenzae Type b (Hib), and Varicella (Chickenpox) Vaccines, and Revised Vaccine Information Materials for Measles, Mumps, Rubella (MMR) Vaccines; Notices

Correction

Notices published in the **Federal Register** on February 23, 1999 [64 FR 9040] beginning on page 9041 make the following corrections:

Polio

On page 9041, 2nd column, under #2: The sentence ''Both vaccines work well.'' should be moved to appear after ''Oral Polio Vaccine Drops by Mouth'' It should read:

IPV
Inactivated Polio Vaccine
A shot
OPV
Oral Polio Vaccine
Drops by mouth
Both vaccines work well.

Page 9041, 3rd column, under #4, last paragraph, 3rd line from end: replace ''helps to protect'' with ''protects''.

Page 9041, 3rd column, heading for #5: should read ''Some Children Should Get Only Shots and Some Should Get Only Drops'' (no period in the middle).

Page 9044, List of Telephone Numbers

Massachusetts: should be (617) 983–6800
Nevada: should be (775) 684–5900
New Hampshire: should be (603) 271–4482
New Jersey: should be (609) 588–7512
Washington state: should be (360) 664–8688

Hepatitis B

Page 9045, 1st column, under #5 near bottom: ''Mild P.problems'' should be ''Mild Problems''

Haemophilus Influenzae Type B

Page 9045, 3rd column, under #1, under bullet Death: ''and nearly 1,000

died.'' should read ''and nearly 1,000 people died.''

On page 9046, 1st column, heading for #5: Should read ''What if there is a moderate or severe reaction?'' (not problem)

All other information and requirements of the notice remain the same.

Dated: March 31, 1999.

Joseph R. Carter,

Acting Associate Director for Management and Operations, Centers for Disease Control and Prevention (CDC).

[FR Doc. 99–8410 Filed 4–5–99; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 99F–0720]

Arakawa Chemical Industries, Ltd.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Arakawa Chemical Industries, Ltd. has filed a petition proposing that the food additive regulations be amended to expand the safe use of hydrogenated aromatic petroleum hydrocarbon resins for use in blends with polymers intended for contact with food.

DATES: Written comments on the petitioner's environmental assessment by May 6, 1999.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Ellen M. Waldron, Center for Food Safety and Applied Nutrition (HFS–215), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–418–3089.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a food additive petition (FAP 9B4653) has been filed by Arakawa Chemical Industries, Ltd., c/o Keller and Heckman, LLP, 1001 G St. NW., suite 500 West, Washington, DC 20001. The petition proposes to amend the food additive regulations in 21 CFR part 178—Indirect Food Additives: Adjuvants, Production Aids, and Sanitizers and in § 177.1520 *Olefin polymers* (21 CFR 177.1520) to expand the safe use of hydrogenated aromatic petroleum hydrocarbon resins, for use in blends with polymers intended for contact with food.

The potential environmental impact of this action is being reviewed. To encourage public participation consistent with regulations issued under the National Environmental Policy Act (40 CFR 1501.4(b)), the agency is placing the environmental assessment submitted with the petition that is the subject of this notice on public display at the Dockets Management Branch (address above) for public review and comment. Interested persons may, on or before May 6, 1999, submit to the Dockets Management Branch (address above) written comments. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday. FDA will also place on public display any amendments to, or comments on, the petitioner's environmental assessment without further announcement in the **Federal Register**. If, based on its review, the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: March 22, 1999.

Laura M. Tarantino,

Acting Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 99–8441 Filed 4–5–99; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 99F–0719]

The Procter & Gamble Co.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that The Procter & Gamble Co. has filed a petition proposing that the food additive regulations be amended to provide for the safe use of olestra in place of fats and oils in prepackaged, unpopped popcorn kernels that are ready-to-heat.

DATES: Written comments on the petitioner's environmental assessment by May 6, 1999.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Mary D. Ditto, Center for Food Safety and Applied Nutrition (HFS–206), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–418–3090.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a food additive petition (FAP 9A4652) has been filed by The Procter & Gamble Co., Winton Hill Technical Center, 6071 Center Hill Ave., Cincinnati, OH 45224. The petition proposes to amend the food additive regulations in § 172.867 *Olestra* (21 CFR 172.867) to provide for the safe use of olestra in place of fats and oils in prepackaged, unpopped popcorn kernels that are ready-to-heat.

The potential environmental impact of this action is being reviewed. To encourage public participation consistent with regulations issued under the National Environmental Policy Act (40 CFR 1501.4(b)), the agency is placing the environmental assessment submitted with the petition that is the subject of this notice on public display at the Dockets Management Branch (address above) for public review and comment. Interested persons may, on or before May 6, 1999, submit to the Dockets Management Branch (address above) written comments. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday. FDA will also place on public display any amendments to, or comments on, the petitioner's environmental assessment without further announcement in the **Federal Register**. If, based on its review, the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).